The role of phototherapy in managing atopic dermatitis: Efficacy and risks
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Phototherapy stands as a paradox within dermatological practice: it employs the very electromagnetic radiation that can damage skin to treat inflammatory skin conditions. Atopic dermatitis, affecting between 15 and 20 percent of children and roughly 7 percent of adults globally, often demands long-term management strategies beyond topical corticosteroids alone. This research examined the comparative effectiveness and safety profile of five phototherapy modalities in patients with moderate-to-severe atopic dermatitis across two Swedish academic centers. A total of 205 patients were enrolled between April 2023 and October 2024 at the Department of Dermatology, Karolinska Institute in Stockholm, and at Uppsala University Hospital. Participants received narrowband ultraviolet B, broadband ultraviolet B, ultraviolet A1, psoralen plus ultraviolet A, or targeted excimer laser therapy over a standardized twelve-week protocol. Disease severity was assessed using the Scoring Atopic Dermatitis index at baseline, six weeks, and twelve weeks, with extended adverse event monitoring continuing through twenty-four weeks. Narrowband ultraviolet B showed the highest enrollment at 42.3 percent of participants, followed by ultraviolet A1 at 24.1 percent. Mean SCORAD scores dropped from 58.4 to 22.1 in the narrowband ultraviolet B group and from 61.7 to 19.3 in the ultraviolet A1 group, representing reductions of 62.2 and 68.7 percent respectively. Erythema was the most frequently reported adverse event across all modalities at 28.4 percent overall incidence. Psoralen plus ultraviolet A carried the highest adverse event burden with erythema in 38.9 percent and hyperpigmentation in 22.2 percent of patients. Skin dryness occurred more often with ultraviolet A1 therapy at 28.4 percent compared to 22.6 percent in narrowband ultraviolet B recipients. No serious adverse events requiring hospitalization were recorded during the observation period. These findings suggest that narrowband ultraviolet B and ultraviolet A1 offer favorable risk-benefit profiles for atopic dermatitis management, while psoralen-based approaches warrant careful patient selection given their higher adverse event rates.
Fields of Study & Subjects
Dermatology and Skin Diseases
Psoriasis: Treatment and Pathogenesis
Cutaneous lymphoproliferative disorders research
Publication details
- Journal / source
- International Journal of Dermatology Sciences
- Volume
- 8
- Issue
- 1
- Pages
- 10–15
- Publication date
- 1 January 2026
- Language
- EN